News Finding: This benefit of anticoagulation was lost after anticoagulation was discontinued.
Paper Finding: However, this benefit of anticoagulation was lost after anticoagulation was discontinued.
News Context: This result was driven by a reduction in the risk of recurrent venous thromboembolism, with the risk of bleeding increasing to a minimal extent. This benefit of anticoagulation was lost after anticoagulation was discontinued. During the 42-month entire study period (including the study treatment and follow-up periods), the composite outcome occurred in 33 patients (21 percent) in the warfarin group and in 42 (24 percent) in the placebo group.
Paper Context: This result was driven by a reduction in the risk of recurrent venous thromboembolism, the risk of bleeding increasing to a minimal extent. However, this benefit of anticoagulation was lost after anticoagulation was discontinued. Consistently with previous studies [7] [8] [9] [10] [11] 23, 24 evaluating substantially prolonged anticoagulation for secondary prophylaxis after a first episode of unprovoked venous thromboembolism, we observed a high absolute rate of recurrent venous thromboembolism in the placebo group during the 18-month treatment period, with a hazard ratio of 0.15 for risk of such events with warfarin.